What long-acting injectable (LAI) antipsychotic medications are available in the U.S.?

See clinical tips available (linked below) on individual LAIs for more detailed information about what clinicians should know.

LAI Drug Name

FDA Indications

(Adult 18+ unless otherwise noted*)

Dosing Tips

(frequency of administration, oral overlap)

***First Generation Antipsychotics***

Schizophrenia

4 weeks

Schizophrenia

2-6 weeks
Overlap PO 4-8 weeks

***Second Generation Antipsychotics***

Schizophrenia 
Bipolar maintenance

8 weeks
Overlap PO 2 weeks

Schizophrenia 
Bipolar maintenance 

4 weeks
Overlap PO 2 weeks

Schizophrenia

4 or 6 or 8 weeks
Aristada Initio IM & PO 1 dose or
Overlap PO 3 weeks

Initiation of Maintenance Aristada (aripiprazole lauroxil LAI) in Schizophrenia

Only for initiation of Aristada once
Given with Aristada first injection

Schizophrenia
Schizoaffective Disorder

4 weeks
Loading IM day 1 & day 8

Schizophrenia

6 months; after adequately treated with INVEGA SUSTENNA for at least 4 months OR INVEGA TRINZA for at least one three-month cycle

Schizophrenia

12 weeks; after adequately treated with INVEGA SUSTENNA for at least four months, with the last 2 doses of INVEGA SUSTENNA at the same dosage strength

Schizophrenia

4 weeks
Subcutaneous (SC)

Schizophrenia 
Bipolar I maintenance 

2 weeks
Overlap PO 3 weeks

Schizophrenia

4 or 8 weeks

Schizophrenia

2 or 4 weeks
Smoking status dosing considerations
Risk: Post-injection delirium sedation syndrome (PDSS) – registry required

If you would like more information on this topic, or would like to provide any feedback, please send us a message using our consultation system. Be sure to let us know about which tip you are writing. We would love to hear from you, and the consultation system is free to use and confidential. Thank you!
  • Was this Helpful ?
  • YesNo

Join our #MissionForBetter now

Sign up for our newsletter. We’ll let you know about new resources, education, and more.

non-image